Phase 2 Immunotherapy Clinical Trials
63 recruitingPhase 2
What is a Phase 2 trial?
Phase 2 trials evaluate whether a treatment works for a specific condition and further assess its safety. These studies typically enroll several hundred participants and provide preliminary data on effectiveness.
Showing 1–20 of 63 trials
Recruiting
Phase 2
A Pilot Study Evaluating β-hydroxybutyrate Supplementation Concomitant to Short-Course Radiotherapy Followed by Immunotherapy Combined With CAPEOX Neoadjuvant Therapy in Patients With Locally Advanced Rectal Cancer
ChemotherapyRectal CancerRadiotherapy+1 more
Tao Zhang25 enrolled1 locationNCT07239466
Recruiting
Phase 2
BITS-TO-HCC Study: HAIC+Iparomlimab/Tuvonralimab + Bevacizumab + SBRT for BCLC-C HCC With PVTT and/or Oligometastases
Hepatocellular CarcinomaRadiotherapyImmunotherapy+3 more
Shandong Cancer Hospital and Institute54 enrolled1 locationNCT07062055
Recruiting
Phase 2
Urinary Tumor DNA-Guided Systemic Immunotherapy for Unresectable Very-High-Risk Non-Muscle-Invasive Bladder Cancer
Bladder CancerImmunotherapyLiquid Biopsy
Tianjin Medical University Second Hospital53 enrolled1 locationNCT07475403
Recruiting
Phase 2
Full-Course Immunotherapy Consolidation for Unfit or Fit B-ALL Who Decline Chemotherapy
Acute Lymphoblastic LeukemiaImmunotherapyBlinatumomab+1 more
The First Affiliated Hospital of Soochow University26 enrolled1 locationNCT06985485
Recruiting
Phase 2
The Efficacy and Safety of Narlumosbart in Combination With Stereotactic Body Radiation Therapy to Improve the Efficacy of First-line Chemotherapy Combined With Immunotherapy in Patients With Bone Metastases From Advanced Non-small Cell Lung Cancer
NSCLCImmunotherapyStereotactic Body Radiation Therapy (SBRT)
Fudan University27 enrolled1 locationNCT06738160
Recruiting
Phase 2
Neoadjuvant Chemoradiotherapy Plus Tislelizumab With or Without Probio-M9 in pMMR/MSS Locally Advanced Rectal Cancer
Neoadjuvant TherapyImmunotherapyTislelizumab+3 more
Seventh Medical Center of PLA General Hospital50 enrolled1 locationNCT07458529
Recruiting
Phase 2
TriCalm Hydrogel® in the Treatment of Immunotherapy-Related Pruritus
Immunotherapy-related Pruritus
University of California, San Diego28 enrolled1 locationNCT06748404
Recruiting
Phase 2
Adaptive Adjuvant Sintilimab Therapy Guided by MRD (ADAPT Lung)
MRDNSCLC (Non-small Cell Lung Cancer)II-IIIB Stages+1 more
Guangdong Association of Clinical Trials115 enrolled2 locationsNCT07120698
Recruiting
Phase 2
Efficacy and Safety of Tislelizumab in Combination With Disitamab-vedotin as Neoadjuvant Therapy for HER2-positive High-risk Upper Tract Urothelial Carcinoma (UTUC)
Neoadjuvant Immunotherapy
Tianjin Medical University Second Hospital21 enrolled1 locationNCT05837806
Recruiting
Phase 2
Phase II Study of Weekly Paclitaxel/Nab-Paclitaxel, Pembrolizumab, and Mirabegron for Recurrent Ovarian Cancer
Ovarian CancerImmunotherapyPembrolizumab
Obstetrics & Gynecology Hospital of Fudan University20 enrolled1 locationNCT07261683
Recruiting
Phase 2
Iparomlimab and Tuvonralimab Combined With Apatinib and Irinotecan Hydrochloride for the Treatment of Advanced Alpha-fetoprotein-producing Gastric Cancer (AFPGC)
ImmunotherapyAFP Gastric or Gastroesophageal Junction AdenocarcinomaPD-1/CTLA-4+1 more
Hebei Medical University Fourth Hospital39 enrolled1 locationNCT07289997
Recruiting
Phase 2
Pembrolizumab With or Without Lenvatinib or Chemotherapy in First-Line Treatment of Advanced Biliary Tract Cancer
Biliary Tract Neoplasms Immunotherapy
Peking Union Medical College Hospital60 enrolled1 locationNCT06230471
Recruiting
Phase 1Phase 2
Personalized Neoantigen Peptide Vaccines for Solid Tumors
Solid TumorsAdvanced CancerRecurrent Cancer+2 more
Seqker Biosciences, Inc.10 enrolled2 locationsNCT07002203
Recruiting
Phase 1Phase 2
Hypofractionated Radiotherapy Combined With Immunochemotherapy for Conversion Treatment of Gastroesophageal Junction Adenocarcinoma
ChemotherapyGastroesophageal Junction AdenocarcinomaImmunotherapy+1 more
West China Hospital88 enrolled4 locationsNCT07072351
Recruiting
Phase 1Phase 2
A Study of ABT-301 Plus Tislelizumab With Bevacizumab in pMMR/Non-MSI-H Locally Advanced or mCRC
ImmunotherapyColorectal Cancer MetastaticColorectal Cancer (CRC)+1 more
Anbogen Therapeutics, Inc.66 enrolled15 locationsNCT07244705
Recruiting
Phase 2
The Safety and Clinical Efficacy of RAK Cell Therapy in Late-stage Gastric Cancer: A Randomized Controlled Trial
Gastric (Stomach) CancerImmunotherapyBiological Therapy
Chinese PLA General Hospital90 enrolled1 locationNCT07212933
Recruiting
Phase 2
SCRT Followed by CAPOX + Bev ± PD-1 Inhibitor for TNT in LARC
Rectal CancerRectal AdenocarcinomaTargeted Therapy+6 more
Ruijin Hospital104 enrolled1 locationNCT07198165
Recruiting
Phase 2Phase 3
Safety and Efficacy Study of Sorbitol With Neoadjuvant Chemotherapy Combined With Tirellizumab (PD-1 Inhibitor) in Patients With Locally Advanced Gastric Cancer
Gastric CancerImmunotherapyNeoadjuvant Therapies+1 more
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology80 enrolled1 locationNCT06826079
Recruiting
Phase 2
Neoadjuvant Radiotherapy Plus Tegafur, Oxaliplatin and Iparomlimab and Tuvonralimab in Resectable Gastric and GE-junction Cancer : A Randomized, Two-arm, Prospective Trial (TRIUNITE-05)
Neoadjuvant TherapyRadiotherapyImmunotherapy+2 more
Daping Hospital and the Research Institute of Surgery of the Third Military Medical University40 enrolled1 locationNCT07165847
Recruiting
Phase 2
Oral Chemotherapy, Targeted Therapy and Immunotherapy With/Without Radiotherapy as 3rd- or Later-line Therapy for Advanced MSS/pMMR Colorectal Cancer
ChemotherapyTargeted TherapyImmunotherapy+2 more
Sun Yat-sen University57 enrolled1 locationNCT06764680